NCT05256641 2026-03-10
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT04002947 2026-02-20
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05583149 2026-01-29
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04604067 2025-12-30
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT05952024 2025-12-22
ACRUE
AstraZeneca
Phase 2 Recruiting
NCT04978584 2025-10-27
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT04189952 2025-05-31
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
Phase 2 Terminated
NCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT05820841 2023-08-31
ARCHED
Universität des Saarlandes
Phase 3 Recruiting
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown